BMS at ECCO 2022

Intended for U.S. scientific audiences only.

The European Crohn’s and Colitis Organization (ECCO) 2022 Congress is an important opportunity to amplify the latest research and breakthroughs for patients with gastrointestinal (GI) immune-mediated diseases. 

Our data at ECCO 2022

Read more about our key data being presented at the meeting.

At ECCO 2022, 10 company-sponsored abstracts will be presented, demonstrating our commitment to addressing unmet needs for patients living with GI immune-mediated diseases.

Our science   

We are pursuing pathbreaking science and innovative research to potentially improve outcomes in GI immune-mediated diseases like inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease. Read how our scientists are addressing some of the most challenging diseases of our time, particularly in gastroenterology.

Winter’s story: living with ulcerative colitis >

Learn about Winter’s journey of living with ulcerative colitis for more than 20 years. 

Inflammatory bowel disease (IBD): research, partnerships and Bristol Myers Squibb’s dedication to patients – a Q&A with Mark Osterman >

Hear how experience as a physician is shaping the approach Mark Osterman, M.D, disease area head, Gastroenterology, is applying to IBD research.

Break the silence: shining a light on inflammatory bowel disease (IBD) >

Learn more from the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) on how “breaking the silence” can make a lasting impact on IBD patients.

Understanding the needs of people living with inflammatory bowel disease (IBD) >

Learn how Bristol Myers Squibb is committed to ongoing research in inflammatory bowel disease.


Learn more about our research in IBD through the resources below.

S1P signaling fact sheet >

Learn about the role of sphingosine-1-phosphate (S1P) signaling and its relationship to gut inflammation.

TYK2 pathway fact sheet >

Learn about the scientific mechanism behind the tyrosine kinase 2 (TYK2) pathway and its role in immune-mediated diseases. is a resource for U.S. healthcare professionals to learn more about our recruiting clinical trials as well as the breadth of our research. 

The IBD Global Assessment of Patient & Physician Unmet Needs Survey (GAPPS) is a resource for U.S. healthcare professionals to learn more about the impact of the evolving IBD treatment landscape on patients with ulcerative colitis and Crohn’s disease.

Crohn's disease fact sheet >

Learn more about Crohn’s disease, a GI immune-mediated disease that affects patients worldwide. 

Ulcerative colitis fact sheet >

Learn more about ulcerative colitis, its symptoms and effects on patients.